We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.
User:Alexander Rudecki/Sandbox 1
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Introduction== | ==Introduction== | ||
| - | ''Drosophila melanogaster'' glutaminyl cyclase (DromeQC) is a globular protein part of the α/β-hydrolase superfamily. DromeQC is an aminoacyltransferase (EC 2.3.2.5) that acts on N-terminal glutamine or glutamate residues, producing a stable cap resistant to protease degradation. The human orthologue of QC (hQC) has been implicated in stabilizing amyloid Aβ peptides involved in neurodegenerative disorders such as Alzheimers<ref>Schilling, S., Zeitschel, U., Hoffmann, T., Heiser, U., Francke, M., Kehlen, A., Holzer, M., Hutter-Paier, B., Prokesch, M., Windisch, M., Jagla, W., Schlenzig, D., Lindner, C., Rudolph, T., Reuter, G., Cynis, H., Montag, D., Demuth, H. U., and Rossner, S. (2008) Glutaminyl cyclase inhibition attenuates pyroglutamate Aà and Alzheimer’s disease-like pathology. Nat. Med. 14, 1106"1111</ref>. It has been shown that DromeQC has a similar overall fold to hQC, as well as a conserved active site. Thus DromeQC is an attractive candidate for transgenic models and mechanistic studies. | + | ''Drosophila melanogaster'' glutaminyl cyclase (DromeQC) is a globular protein part of the α/β-hydrolase superfamily. DromeQC is an aminoacyltransferase (EC 2.3.2.5) that acts on N-terminal glutamine or glutamate residues, producing a stable cap resistant to protease degradation. The human orthologue of QC (hQC) has been implicated in stabilizing amyloid Aβ peptides involved in neurodegenerative disorders such as Alzheimers<ref>{{cite book |authors:Schilling, S., Zeitschel, U., Hoffmann, T., Heiser, U., Francke, M., Kehlen, A., Holzer, M., Hutter-Paier, B., Prokesch, M., Windisch, M., Jagla, W., Schlenzig, D., Lindner, C., Rudolph, T., Reuter, G., Cynis, H., Montag, D., Demuth, H. U., and Rossner, S. (2008) Glutaminyl cyclase inhibition attenuates pyroglutamate Aà and Alzheimer’s disease-like pathology. Nat. Med. 14, 1106"1111}}</ref>. It has been shown that DromeQC has a similar overall fold to hQC, as well as a conserved active site. Thus DromeQC is an attractive candidate for transgenic models and mechanistic studies. |
===Gene=== | ===Gene=== | ||
==Structure== | ==Structure== | ||
Revision as of 19:35, 23 March 2014
Introduction
Drosophila melanogaster glutaminyl cyclase (DromeQC) is a globular protein part of the α/β-hydrolase superfamily. DromeQC is an aminoacyltransferase (EC 2.3.2.5) that acts on N-terminal glutamine or glutamate residues, producing a stable cap resistant to protease degradation. The human orthologue of QC (hQC) has been implicated in stabilizing amyloid Aβ peptides involved in neurodegenerative disorders such as Alzheimers[1]. It has been shown that DromeQC has a similar overall fold to hQC, as well as a conserved active site. Thus DromeQC is an attractive candidate for transgenic models and mechanistic studies.
Gene
Structure
| |||||||||||
